In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery

Abstract

Objective: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aimof this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based onneoadjuvant chemotherapy (NAC).Material and Methods: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed.Results: A total of 99 patients with a median age of 59.0 years (range, 22-87 years) were studied. The median follow-up time was 39±32.7months, 81 patients (81.8%) died and 18 patients (18.2%) were alive. The five-year survival rate was 27.6%. Of the patients, 37 (37.4%) wereunderwent surgery after NAC, 62 (62.3%) were primary. More patients with NAC died within 3 years compared with those without NAC (83.9%vs 56.0%) (p=0.015). Patients with NAC had less tumor spread (presence of visible tumor in the upper abdomen during surgery) (29.7% vs72.6%; p